RxDoctor Payments DataLook up a doctor →

Vadsana Smith, APRN

Nurse Practitioner · Independence, MONPI 1669540357

Payments from drug & device makers

$11,987in general payments, 2019–2025

Across 578 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • QOL Medical, LLC$653
  • Pfizer$604
  • plus $4K from 25 others

What the payments were for

  • Food & beverage$11,74698%
  • Education$2412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,987 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$21,081
Medicare patients
121
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin14$51,266
LinzessLinaclotide18$21,867
Mesalamine12$4,765
Colestipol Hcl40$3,538
Pantoprazole Sodium158$2,095
Omeprazole87$1,557
Esomeprazole Magnesium13$805
Dicyclomine Hcl29$800
Sucralfate17$672
Famotidine57$641
Ondansetron OdtOndansetron13$450
Spironolactone22$205
Furosemide15$25

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,392$51,26614 claims
AbbVieLinzess$2,445$21,86718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Independence

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →